Xu, Yi

Beth Israel Deaconess Medical Center · Sanofi (France) · Massachusetts General Hospital · Dana-Farber Cancer Institute · Vall d'Hebron Institute of Oncology

1 paper on CoChatORCID 0000-0002-5361-1812

Most cited papers

Verified
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research
PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies
Cited by 152

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free